Novo Nordisk garners FDA approval; Genetic tests ID the right diet;

 @FierceBiotech: Pharma reports 26,000 layoffs in 2010. Report | Follow @FierceBiotech

 @JohnCFierce: Archimedes CEO tells me he's looking to build small, 50-100, US sales force for PecFent. Article | Follow @JohnCFierce

> The FDA has approved Novo Nordisk's growth hormone injection pen. Story

> The U.S. based Stemgent is investing $4.5 million into a Scottish start-up which will develop cell signaling products it can then turn around and market. Ubiquigent will be based in Dundee, Scotland. Report

> TopoTarget is getting an $8.17 million payday from SpePharm in exchange for some of the world rights to Savene, its anthracycline extravasation treatment. TopoTarget says the deal will free the company to focus on its lead cancer program. Story

> A contract to supply the U.S. government with its anthrax vaccine helped Human Genome Sciences post a small profit for 2009. HGS also raised $818.7 million from the sale of shares. Report

> Shares of Nektar Therapeutics surged yesterday after analysts offered some bullish comments regarding likely advances for its drug pipeline. Story

And Finally... Stanford researchers say a genetic test can be used to accurately predict what kind of diet is most likely to lead to significant weight loss. Women genetically inclined to lose weight through a low-carb diet, for example, lost two and a half times more weight than women without the same genetic profile. Article

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.